Sangamo launches auction for ST-503 pain program as Chapter 11 asset sales close with $163.55 million proceeds
Bitget2026/10/13 20:01- Sangamo set a fourth-quarter 2026 deadline for an auction of its clinical-stage ST-503 chronic neuropathic pain program.
- Asset sales completed through a court-supervised Section 363 process generated USD 163.55 million in gross cash proceeds.
- PTC bought the Fabry disease program ST-920 for USD 111 million in cash, with up to USD 100 million in milestone payments.
- Lilly acquired Sangamo’s capsid delivery, zinc finger and MINT platforms, with the ST-506 prion disease program, for USD 50 million in cash.
- Proceeds were used to repay all outstanding amounts under the debtor-in-possession financing facility provided by Future Solutions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Data: BTC falls below $80,000
Apple (AAPL.US) ends the "touchscreen ban" from the Jobs era! The first touchscreen laptop, the OLED MacBook Pro, will go on sale on November 6th!
The new Apple (AAPL.US) CEO has ended the "touchscreen ban" of the Steve Jobs era! The first touchscreen OLED MacBook Pro will go on sale on November 6th!
Aurora (AUR.US) mass production of driverless trucks delayed again: this year's target of 200 units missed, 2026 revenue expectations unmet, projected to return to normal in 2027
Aurora Innovation Inc. announced during its quarterly earnings release on Wednesday (U.S. Eastern time) that it is expected to miss its production target for this year, but noted that it is likely to get back on track by 2027.
Crypto prices
More
